We are live on ! Find out more
PETS icon

PetMed Express

1.19 USD
+0.01
0.85%
At close Updated Oct 30, 4:00 PM EDT
1 day
0.85%
5 days
-2.46%
1 month
-13.77%
3 months
-39.9%
6 months
-46.88%
Year to date
-63.94%
1 year
-52.78%
5 years
-95.92%
10 years
-94.01%
 

About: PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.

Employees: 189

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 88.9%
Negative 11.1%
Neutral
GlobeNewsWire
4 days ago
PetMed Express, Inc. to Report Second Quarter Fiscal Year 2027 Financial Results on Tuesday, November 10, 2026
DELRAY BEACH, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the second quarter fiscal year ended September 30, 2026, on Tuesday, November 10, 2026 after market close. The Company will host a conference call and webcast to review these results at 4:30pm Eastern Time on the same day.
PetMed Express, Inc. to Report Second Quarter Fiscal Year 2027 Financial Results on Tuesday, November 10, 2026
Neutral
GlobeNewsWire
29 days ago
PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that PetMeds recently granted equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment.
PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
1 month ago
PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director
Dr. Elkeles Brings Deep Experience and Proven Track Record in Shaping Human Capital Strategy to Support Strategic Growth and Operational Execution Dr. Elkeles Brings Deep Experience and Proven Track Record in Shaping Human Capital Strategy to Support Strategic Growth and Operational Execution
PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director
Neutral
GlobeNewsWire
1 month ago
PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition
Justin Mennen to Succeed Leslie C.G. Campbell as Chair of the Board Following Her Retirement Justin Mennen to Succeed Leslie C.G. Campbell as Chair of the Board Following Her Retirement
PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition
Neutral
GlobeNewsWire
1 month ago
PetMeds Appoints Andrew Parry as Chief Technology Officer
DELRAY BEACH, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Andrew Parry as Chief Technology Officer, effective immediately. Parry will lead the Company's technology strategy, platform architecture and engineering execution across its e-commerce, pharmacy and enterprise systems.
PetMeds Appoints Andrew Parry as Chief Technology Officer
Neutral
Zacks Investment Research
2 months ago
PetMed Express Q1 Earnings Miss Estimates, Sales Decline Y/Y
PETS' fiscal first-quarter 2027 sales decline year over year, but lower costs, stronger recurring sales and new partnerships offer signs of progress.
PetMed Express Q1 Earnings Miss Estimates, Sales Decline Y/Y
Negative
Zacks Investment Research
2 months ago
PetMed (PETS) Reports Q1 Loss, Misses Revenue Estimates
PetMed (PETS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of $0.12. This compares to a loss of $0.34 per share a year ago.
PetMed (PETS) Reports Q1 Loss, Misses Revenue Estimates
Neutral
Seeking Alpha
2 months ago
PetMed Express, Inc. (PETS) Q1 2027 Earnings Call Prepared Remarks Transcript
PetMed Express, Inc. (PETS) Q1 2027 Earnings Call Prepared Remarks Transcript
PetMed Express, Inc. (PETS) Q1 2027 Earnings Call Prepared Remarks Transcript
Neutral
GlobeNewsWire
2 months ago
PetMeds® Announces First Quarter Financial Results
DELRAY BEACH, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2026.
PetMeds® Announces First Quarter Financial Results
Neutral
GlobeNewsWire
3 months ago
PetMed Express, Inc. to Report First Quarter Fiscal Year 2027 Financial Results on Thursday, August 13, 2026
DELRAY BEACH, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the first quarter fiscal year ended June 30, 2026, on Thursday, August 13, 2026 after market close. The Company will host a conference call and webcast to review these results at 4:30pm Eastern Time on the same day.
PetMed Express, Inc. to Report First Quarter Fiscal Year 2027 Financial Results on Thursday, August 13, 2026
Price charts implemented using Lightweight Charts™